Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Forma Therapeutics Inc (Forma), a subsidiary of Novo Nordisk AS, is a biotech company. It develops technologies to identify the initial molecules that provide drug discovery programs. The company's pipeline products include etavopivat, hbf inducer, membrane stabilizer, FT-7051, FT-3171, synthetic lethality, olutasidenib and B1-1701963 among others. It offers services for hematological disease, acute myeloid leukemia, brain tumors, sickle cell disease and others. The company collaborates with biotechnology companies, pharmaceuticals and biomedicine companies and research institutes for its research and development activities. It operates offices in Watertown and Branford, the US. FORMA is headquartered in Watertown, Massachusetts, the US.
Headquarters
United States of America
Address
Suite 501, 300 North Beacon Street, Watertown, Massachusetts, 02472
Website
www.novonordisk.com/
Telephone
+1 617 6791970
Industry
Pharmaceuticals and Healthcare
Products and Services
| Products |
|---|
| Pipeline |
| Etavopivat |
| Hbf Inducer |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Forma Therapeutics Inc | Abeona Therapeutics Inc | 21st Century Therapeutics Inc | Formula Pharmaceuticals Inc | Immunitas Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Watertown | Cleveland | Detroit | Berwyn | Waltham |
| State/Province | Massachusetts | Ohio | Michigan | Pennsylvania | Massachusetts |
| No. of Employees | - | 84 | - | - | - |
| Entity Type | Private | Public | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lars Fruergaard Jorgensen | President - Novo Nordisk; Chief Executive Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer